ATE251901T1 - Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson - Google Patents
Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinsonInfo
- Publication number
- ATE251901T1 ATE251901T1 AT01111109T AT01111109T ATE251901T1 AT E251901 T1 ATE251901 T1 AT E251901T1 AT 01111109 T AT01111109 T AT 01111109T AT 01111109 T AT01111109 T AT 01111109T AT E251901 T1 ATE251901 T1 AT E251901T1
- Authority
- AT
- Austria
- Prior art keywords
- parkinson
- therapeutic system
- transdermal therapeutic
- rotigotin
- achievement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111109A EP1256339B1 (de) | 2001-05-08 | 2001-05-08 | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE251901T1 true ATE251901T1 (de) | 2003-11-15 |
Family
ID=8177356
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01111109T ATE251901T1 (de) | 2001-05-08 | 2001-05-08 | Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson |
AT02740569T ATE444061T1 (de) | 2001-05-08 | 2002-05-06 | Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02740569T ATE444061T1 (de) | 2001-05-08 | 2002-05-06 | Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln |
Country Status (15)
Country | Link |
---|---|
EP (3) | EP1256339B1 (de) |
JP (2) | JP5026656B2 (de) |
KR (1) | KR100974974B1 (de) |
CN (2) | CN1606435A (de) |
AT (2) | ATE251901T1 (de) |
CY (1) | CY1109861T1 (de) |
DE (2) | DE60100994T2 (de) |
DK (2) | DK1256339T3 (de) |
ES (2) | ES2204780T3 (de) |
HK (1) | HK1049444B (de) |
HU (1) | HU229350B1 (de) |
PT (2) | PT1256339E (de) |
RU (1) | RU2272625C2 (de) |
WO (1) | WO2002089778A2 (de) |
ZA (1) | ZA200209982B (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60100595T2 (de) * | 2001-05-08 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (de) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasale formulierung enthaltend |
DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
JP2008514376A (ja) * | 2004-09-29 | 2008-05-08 | シュウォーツ ファーマ インコーポレイテッド | パーキンソン病のための経皮治療システム |
CN101147739B (zh) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
EP2490673A2 (de) * | 2009-10-19 | 2012-08-29 | Actavis Group Ptc Ehf | Amorphe rotigotin-copräzipitate |
DK2515887T3 (en) | 2009-12-22 | 2018-09-17 | Ucb Biopharma Sprl | Polyvinylpyrrolidone to stabilize a solid dispersion of the non-crystalline form of rotigotine |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
KR102364378B1 (ko) * | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | 안정성을 향상시킨 로티고틴 함유 경피흡수제제 |
DE102014114282A1 (de) | 2014-10-01 | 2016-04-07 | Neuraxpharm Arzneimittel Gmbh | Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson |
WO2018123822A1 (ja) | 2016-12-28 | 2018-07-05 | 久光製薬株式会社 | ブトルファノール含有貼付剤 |
DE102018120505A1 (de) | 2017-10-20 | 2019-04-25 | Amw Gmbh | Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen |
DK3854388T3 (da) | 2020-01-24 | 2023-11-27 | Luye Pharma Switzerland Ag | Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0751515B2 (ja) * | 1986-09-10 | 1995-06-05 | 明治製菓株式会社 | 経皮吸収製剤 |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
-
2001
- 2001-05-08 EP EP01111109A patent/EP1256339B1/de not_active Expired - Lifetime
- 2001-05-08 ES ES01111109T patent/ES2204780T3/es not_active Expired - Lifetime
- 2001-05-08 DK DK01111109T patent/DK1256339T3/da active
- 2001-05-08 DE DE60100994T patent/DE60100994T2/de not_active Expired - Lifetime
- 2001-05-08 AT AT01111109T patent/ATE251901T1/de active
- 2001-05-08 EP EP03013353A patent/EP1344522A1/de not_active Withdrawn
- 2001-05-08 PT PT01111109T patent/PT1256339E/pt unknown
-
2002
- 2002-05-06 CN CNA028015401A patent/CN1606435A/zh active Pending
- 2002-05-06 PT PT02740569T patent/PT1471892E/pt unknown
- 2002-05-06 HU HU0500525A patent/HU229350B1/hu unknown
- 2002-05-06 AT AT02740569T patent/ATE444061T1/de active
- 2002-05-06 JP JP2002586915A patent/JP5026656B2/ja not_active Expired - Lifetime
- 2002-05-06 DE DE60233898T patent/DE60233898D1/de not_active Expired - Lifetime
- 2002-05-06 KR KR1020037000143A patent/KR100974974B1/ko active IP Right Grant
- 2002-05-06 ES ES02740569T patent/ES2331787T3/es not_active Expired - Lifetime
- 2002-05-06 CN CN2011100516651A patent/CN102172351B/zh not_active Expired - Lifetime
- 2002-05-06 RU RU2003133217/15A patent/RU2272625C2/ru active IP Right Revival
- 2002-05-06 WO PCT/EP2002/004976 patent/WO2002089778A2/en active IP Right Grant
- 2002-05-06 DK DK02740569T patent/DK1471892T3/da active
- 2002-05-06 EP EP02740569A patent/EP1471892B1/de not_active Revoked
- 2002-12-10 ZA ZA200209982A patent/ZA200209982B/xx unknown
-
2003
- 2003-03-04 HK HK03101599.0A patent/HK1049444B/zh unknown
-
2009
- 2009-11-05 CY CY20091101150T patent/CY1109861T1/el unknown
-
2010
- 2010-01-07 JP JP2010002209A patent/JP2010106037A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102172351A (zh) | 2011-09-07 |
HUP0500525A2 (hu) | 2005-09-28 |
HK1049444B (zh) | 2004-03-19 |
PT1256339E (pt) | 2004-02-27 |
RU2003133217A (ru) | 2005-04-20 |
PT1471892E (pt) | 2009-12-23 |
DK1256339T3 (da) | 2004-02-09 |
JP5026656B2 (ja) | 2012-09-12 |
DE60100994T2 (de) | 2004-07-22 |
ZA200209982B (en) | 2003-03-24 |
EP1471892B1 (de) | 2009-09-30 |
ES2204780T3 (es) | 2004-05-01 |
DE60100994D1 (de) | 2003-11-20 |
CN102172351B (zh) | 2013-07-17 |
EP1471892A2 (de) | 2004-11-03 |
EP1344522A1 (de) | 2003-09-17 |
WO2002089778A2 (en) | 2002-11-14 |
KR100974974B1 (ko) | 2010-08-09 |
RU2272625C2 (ru) | 2006-03-27 |
CN1606435A (zh) | 2005-04-13 |
DK1471892T3 (da) | 2009-12-07 |
HK1049444A1 (en) | 2003-05-16 |
ES2331787T3 (es) | 2010-01-15 |
EP1256339A1 (de) | 2002-11-13 |
DE60233898D1 (de) | 2009-11-12 |
HU229350B1 (en) | 2013-11-28 |
KR20030016373A (ko) | 2003-02-26 |
EP1256339B1 (de) | 2003-10-15 |
JP2004536054A (ja) | 2004-12-02 |
ATE444061T1 (de) | 2009-10-15 |
JP2010106037A (ja) | 2010-05-13 |
CY1109861T1 (el) | 2014-09-10 |
WO2002089778A3 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE251901T1 (de) | Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson | |
PT1256340E (pt) | Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson | |
BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
HUP0401568A2 (hu) | Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények | |
BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
HUP0203590A2 (hu) | Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére | |
AU1046202A (en) | Transdermal therapeutic system for treating restless-legs-syndrome | |
HUP0102728A2 (hu) | Módszerek és transzdermális készítmények fájdalom csillapítására | |
ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
EA200400691A1 (ru) | Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
DE602004025040D1 (de) | Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid | |
WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
TR200301916T4 (tr) | Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1256339 Country of ref document: EP |
|
EEIH | Change in the person of patent owner |